No connection

Search Results

JNJ vs KURA

JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%
KURA
Kura Oncology, Inc.
BEARISH
Price
$8.67
Market Cap
$765.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
JNJ
21.55
KURA
--
Forward P/E
JNJ
18.9
KURA
-3.55
P/B Ratio
JNJ
7.03
KURA
4.37
P/S Ratio
JNJ
6.09
KURA
11.35
EV/EBITDA
JNJ
17.81
KURA
-0.39

Profitability

Gross Margin
JNJ
68.08%
KURA
-272.14%
Operating Margin
JNJ
23.97%
KURA
-497.62%
Profit Margin
JNJ
28.46%
KURA
0.0%
ROE
JNJ
35.03%
KURA
-94.82%
ROA
JNJ
8.68%
KURA
-25.33%

Growth

Revenue Growth
JNJ
9.1%
KURA
-67.8%
Earnings Growth
JNJ
48.6%
KURA
--

Financial Health

Debt/Equity
JNJ
0.6
KURA
0.12
Current Ratio
JNJ
1.03
KURA
6.06
Quick Ratio
JNJ
0.69
KURA
5.81

Dividends

Dividend Yield
JNJ
2.19%
KURA
--
Payout Ratio
JNJ
46.6%
KURA
0.0%

AI Verdict

JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69
KURA BEARISH

KURA presents a contradictory profile with a stable Piotroski F-Score of 6/9 and exceptional liquidity (Current Ratio 6.06), yet suffers from severe fundamental decay. The company has experienced a catastrophic revenue decline of -67.80% YoY and has missed earnings estimates in four consecutive quarters with an average surprise of -50.91%. While the analyst target price of $31.82 suggests significant upside, this is decoupled from the current financial reality of negative gross margins (-272.14%) and bearish insider activity. The stock is currently a speculative play on pipeline success rather than a value or growth investment based on existing data.

Strengths
Strong liquidity position with a Current Ratio of 6.06
Very low leverage with a Debt/Equity ratio of 0.12
Stable Piotroski F-Score (6/9) indicating baseline operational stability
Risks
Severe revenue contraction (-67.80% YoY and Q/Q)
Consistent earnings misses (0/4 beats in the last year)
Deeply negative profitability (Operating Margin -497.62%)

Compare Another Pair

JNJ vs KURA: Head-to-Head Comparison

This page compares Johnson & Johnson (JNJ) and Kura Oncology, Inc. (KURA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile